Search Results 981-990 of 17578 for Assay
Participation eligibility · Patients with active tuberculosis should be excluded; · Patients will be screened with Interferon Gamma Release Assay (IGRA) such as ...
GRAIL is using deep sequencing of circulating cell-free nucleic acids (cfNAs) to develop assays to detect cancer early in blood. The purpose of this study ...
... assays into clinical tests. Cancer genomics. Dr. Hart works toward integrated next-generation sequencing data analysis of multiple genomic features, such as ...
Documented positive anti-mitochondrial antibody (AMA) titer (>1:40 titer on immunofluorescence or M2 positive by enzyme-linked immunosorbent assay) or PBC ...
Serum free light chain (FLC) assay: involved FLC level greater or equal to 10 mg/dL (100 mg/L) provided serum FLC ratio is abnormal. For Part A (Dose ...
... assay) at a central laboratory. Formalin-fixed, paraffin-embedded (FFPE) tissue blocks are preferred to slides. Newly obtained biopsies are preferred to ...
An archival tumor sample from the time of initial diagnosis or last morphological relapse must be available to calibrate the NGS MRD assay. Cohort IIC ...
Unable to withdraw the following medications that alter GI transit for 72 hours prior to baseline colonic transit assay through the duration of treatment ...
Development and validation of a microRNA-based diagnostic assay for classification of renal cell carcinomas. Mol Oncol. 2013 Jun; 7(3):732-8. Epub 2013 Mar ...
Ryan is a senior research technologist who oversees all day-to-day laboratory operations and has expertise in tissue culture, mitochondrial physiology assays ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your gift to celebrate this day advances our doctors’ lifesaving work.